amitriptylinoxide Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Amitriptylinoxide, or amitriptyline N-oxide, is a tricyclic antidepressant (TCA) which was introduced in Europe in the 1970s for the treatment of depression.   Wikipedia

Chemistry

  • SMILES: C[N+](C)([O-])CCC=C1c2ccccc2CCc2ccccc21
  • InChIKey: ZPMKQFOGINQDAM-UHFFFAOYSA-N
  • Mol. Mass: 293.41
  • ALogP: 4.18
  • ChEMBL Molecule:
    amitriptylinoxide  
More Chemistry

Pharmacology

Alternative names

amioxid-neuraxpharm | amitriptyline n-oxide | amitriptyline oxide | amitriptylinoxide | amitryptyline-n-oxide | equilibrin | neuraxpharm brand of amitriptylinoxide

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Depression

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 4)

Psychophysiologic Disorders (Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue